Inhibrx Biosciences, spun off in 2024 from Inhibrx, Inc., develops novel multivalent biologic therapies targeting oncology indications. Its lead clinical programs, ozekibart (INBRX-109) and INBRX-106, employ proprietary modular protein engineering platforms designed for optimized agonist function. While early revenue increased to $1.3 million in 2025, the company remains unprofitable with operating losses narrowing to $135 million. Cash reserves of $124 million provide runway amid a $175 million secured loan subject to restrictive covenants. Management is exploring strategic alternatives for ozekibart monetization, underscoring both growth potential and execution risks. The firm faces typical biotech challenges including regulatory uncertainty, competitive pressures, and the need to build commercialization capabilities.